Xeris Biopharma Holdings Inc.
10/14/2026 | Press release | Distributed by Public on 10/14/2026 05:08
Material Event (Form 8-K)
Item 8.01 Other Events
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey against defendants (i) Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, and Lemed Specialty Pharmacy Arizona, LLC; and (ii) Rising Pharma Holdings, Inc. and Rising Pharma Specialties Pvt. Ltd. in two separate actions. These lawsuits were filed following the grant of U.S. Patent No. 12,758,502 (the "'502 patent") related to the Company's KEVEYIS® (dichlorphenamide) product.
The complaints allege that each of the defendants will infringe the '502 patent by making, using, selling, offering for sale, and/or importing their generic dichlorphenamide products. The Company is seeking a judgment of infringement, injunctive relief prohibiting further infringement, monetary damages adequate to compensate for the infringement, enhanced damages where permitted by law, attorneys' fees, costs, and such other relief as the court deems appropriate.
Xeris Biopharma Holdings Inc. published this content on October 14, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 14, 2026 at 11:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]